Neurelis Announces 16 Poster Presentations at the Annual Meeting of the American Epilepsy Society

/PRNewswire/ -- Neurelis, Inc. will present a collection of 16 posters describing safety, tolerability and effectiveness results observed in trials evaluating...

Related Keywords

United States ,Chicago ,Illinois ,American ,Enrique Carrazana ,Adrianl Rabinowicz ,Mark Leonard ,School Setting ,American Epilepsy Society ,Timing To Administration ,Drug Administration ,School Nurse Survey To Understand Current Practices ,Neurelis Inc ,Second Dose Administration ,Clinical Development ,American Epilepsy Society December ,Neurelis Chief Medical Officer ,Drug Exclusivity ,Senior Vice President ,Medical Affairs ,Nasal Spray ,Second Dose Administration Within ,Population Pharmacokinetic ,Open Label Pharmacokinetic ,Safety Trial ,Diazepam Nasal Spray ,Old With Seizure ,Epilepsy Scale From ,Long Term Safety Study ,Self Administering Diazepam Nasal Spray ,Seizure Clusters ,Tolerance With Diazepam Nasal Spray ,Seizure Clusters After Long Term Use ,Final Results From ,Repeat Dose Safety ,Study Endpoints ,Patients Discontinuing From ,Safety Study ,Acute Treatment ,Treatment Satisfaction ,Diazepam Nasal Spray Rescue Therapy ,Results From ,Long Term Open Label ,Pediatric Patients ,Epileptic Encephalopathy ,Seasonal Allergies ,Rhinitis History ,Patients With Seizure Clusters ,Tolerability Endpoints Relevant ,Open Label Repeat Dose Safety Study ,Patients With Seizure ,School Nurse Survey ,Understand Current Practices ,Epilepsy Scale ,Infrequent Users ,Second Doses ,Age Subgroups ,Second Dose ,Diazepam Nasal Spray Within ,Seizure Clusters Concomitantly Receiving Clobazam ,Subgroup Analysis ,Completed Phase ,Open Label Safety ,Neurelis Orphan Drug Exclusivity ,Safety Information ,Nervous System ,Serious Adverse Reactions ,Benzyl Alcohol ,Boxed Warning ,More Information ,Neurelis ,Nc ,